Recent Advances in Remote Pulmonary Artery Pressure Monitoring for Patients with Chronic Heart Failure: Current Evidence and Future Perspectives

Clephas, Pascal R.D.; Aydin, Dilan; Radhoe, Sumant P; Brugts, Jasper J.

doi:10.3390/s23031364

Cited by 9 publications

(8 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This allowed for the early detection of cardiac decompensation, which improved clinical outcomes and reduced hospital visits for these patients. The study by Stehlik et al included monitoring the vitals of 100 heart failure patients in real time using wearable sensors that recorded their core body temperature, skin impedance, and ECG waveform [ 58 ]. Hospitalizations due to HF exacerbation were predicted with 76% sensitivity and 85% specificity using data evaluated using similarity-based modeling [ 59 ].…”

Section: Reviewmentioning

confidence: 99%

Early Diagnosis of Cardiovascular Diseases in the Era of Artificial Intelligence: An In-Depth Review

Almansouri,

Awe,

Rajavelu

et al. 2024

Cureus

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are significant health issues that result in high death rates globally. Early detection of cardiovascular events may lower the occurrence of acute myocardial infarction and reduce death rates in people with CVDs. Traditional data analysis is inadequate for managing multidimensional data related to the risk prediction of CVDs, heart attacks, medical image interpretations, therapeutic decision-making, and disease prognosis due to the complex pathological mechanisms and multiple factors involved. Artificial intelligence (AI) is a technology that utilizes advanced computer algorithms to extract information from large databases, and it has been integrated into the medical industry. AI methods have shown the ability to speed up the advancement of diagnosing and treating CVDs such as heart failure, atrial fibrillation, valvular heart disease, hypertrophic cardiomyopathy, congenital heart disease, and more. In clinical settings, AI has shown usefulness in diagnosing cardiovascular illness, improving the efficiency of supporting tools, stratifying and categorizing diseases, and predicting outcomes. Advanced AI algorithms have been intricately designed to analyze intricate relationships within extensive healthcare data, enabling them to tackle more intricate jobs compared to conventional approaches.

show abstract

Section: Reviewmentioning

confidence: 99%

Early Diagnosis of Cardiovascular Diseases in the Era of Artificial Intelligence: An In-Depth Review

Almansouri,

Awe,

Rajavelu

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Therefore, the role of decongestion currently remains to stabilize patients with AHF quickly and facilitate the subsequent implementation of disease-modifying treatments. Nevertheless, recent data with remote monitoring of pulmonary pressures, allowing careful, individually titrated decongestive treatment (mainly with diuretics), suggest that a favorable impact on heart failure readmissions remains a distinct possibility, which should be the topic of further study [6 ▪ ].…”

Section: Decongestive Treatment In Heart Failurementioning

confidence: 99%

Decongestion (instead of ultrafiltration?)

Schuermans,

Verbrugge

2024

Current Opinion in Cardiology

View full text Add to dashboard Cite

Purpose of review To summarize the contemporary evidence on decongestion strategies in patients with acute heart failure (AHF). Recent findings While loop diuretic therapy has remained the backbone of decongestive treatment in AHF, multiple randomized clinical trials suggest that early combination with other diuretic classes or molecules with diuretic properties should be considered. Mineralocorticoid receptor antagonists and sodium–glucose co-transporter-2 inhibitors are disease-modifying drugs in heart failure that favourably influence prognosis early on, advocating their start as soon as possible in the absence of any compelling contraindications. Short-term upfront use of acetazolamide in adjunction to intravenous loop diuretic therapy relieves congestion faster, avoids diuretic resistance, and may shorten hospitalization length. Thiazide-like diuretics remain a good option to break diuretic resistance. Currently, ultrafiltration in AHF remains mainly reserved for patient with an inadequate response to pharmacological treatment. Summary In most patients with AHF, decongestion can be achieved effectively and safely through combination diuretic therapies. Appropriate diuretic therapy may shorten hospitalization length and improve quality of life, but has not yet proven to reduce death or heart failure readmissions. Ultrafiltration currently has a limited role in AHF, mainly as bail-out strategy, but evidence for a more upfront use remains inconclusive.

show abstract

“…Currently, CardioMEMS is the only PA pressure sensor approved for routine clinical use with both U.S. Food and Drug Administration (FDA) clearance and European Conformity (CE) mark. Another similar device, the CordellaTM Pulmonary Artery Pressure Sensor System (Endotronix, Inc., Chicago, IL, USA) [32], is also capable of remotely measuring PA pressures and is under investigation. The CordellaTM sensor operates on similar hemodynamic principles as CardioMEMS but is integrated with the CordellaTM Heart Failure System (CHFS), offering additional vital parameter monitoring such as blood pressure, heart rate, weight, and oxygen saturation.…”

Section: State Of the Art Of Mems In Heart Failurementioning

confidence: 99%

MEMS Technology in Cardiology: Advancements and Applications in Heart Failure Management Focusing on the CardioMEMS Device

Ciotola,

Pyxaras,

Rittger

et al. 2024

Sensors

View full text Add to dashboard Cite

Heart failure (HF) is a complex clinical syndrome associated with significant morbidity, mortality, and healthcare costs. It is characterized by various structural and/or functional abnormalities of the heart, resulting in elevated intracardiac pressure and/or inadequate cardiac output at rest and/or during exercise. These dysfunctions can originate from a variety of conditions, including coronary artery disease, hypertension, cardiomyopathies, heart valve disorders, arrhythmias, and other lifestyle or systemic factors. Identifying the underlying cause is crucial for detecting reversible or treatable forms of HF. Recent epidemiological studies indicate that there has not been an increase in the incidence of the disease. Instead, patients seem to experience a chronic trajectory marked by frequent hospitalizations and stagnant mortality rates. Managing these patients requires a multidisciplinary approach that focuses on preventing disease progression, controlling symptoms, and preventing acute decompensations. In the outpatient setting, patient self-care plays a vital role in achieving these goals. This involves implementing necessary lifestyle changes and promptly recognizing symptoms/signs such as dyspnea, lower limb edema, or unexpected weight gain over a few days, to alert the healthcare team for evaluation of medication adjustments. Traditional methods of HF monitoring, such as symptom assessment and periodic clinic visits, may not capture subtle changes in hemodynamics. Sensor-based technologies offer a promising solution for remote monitoring of HF patients, enabling early detection of fluid overload and optimization of medical therapy. In this review, we provide an overview of the CardioMEMS device, a novel sensor-based system for pulmonary artery pressure monitoring in HF patients. We discuss the technical aspects, clinical evidence, and future directions of CardioMEMS in HF management.

show abstract

Recent Advances in Remote Pulmonary Artery Pressure Monitoring for Patients with Chronic Heart Failure: Current Evidence and Future Perspectives

Cited by 9 publications

References 68 publications

Early Diagnosis of Cardiovascular Diseases in the Era of Artificial Intelligence: An In-Depth Review

Early Diagnosis of Cardiovascular Diseases in the Era of Artificial Intelligence: An In-Depth Review

Decongestion (instead of ultrafiltration?)

MEMS Technology in Cardiology: Advancements and Applications in Heart Failure Management Focusing on the CardioMEMS Device

Contact Info

Product

Resources

About